<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01958372</url>
  </required_header>
  <id_info>
    <org_study_id>2013-021</org_study_id>
    <secondary_id>NCI-2013-01835</secondary_id>
    <secondary_id>1307012220</secondary_id>
    <secondary_id>2013-021</secondary_id>
    <secondary_id>P30CA022453</secondary_id>
    <nct_id>NCT01958372</nct_id>
  </id_info>
  <brief_title>Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase I Study of Thoracic Radiotherapy and Concurrent Chemotherapy With Soy Isoflavones in Stage III NSCLC (Non-Small Cell Lung Cancer) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects of soy isoflavones when given together with&#xD;
      radiation therapy and chemotherapy in treating patients with stage IIIA-IIIB non-small cell&#xD;
      lung cancer. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in&#xD;
      chemotherapy, such as cisplatin, pemetrexed sodium, and etoposide, work in different ways to&#xD;
      stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Soy isoflavones may help radiation therapy, cisplatin, pemetrexed sodium, and&#xD;
      etoposide work better by making tumor cells more sensitive to the drug. Soy isoflavones may&#xD;
      also protect normal cells from the side effects of radiation therapy and chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the safety of adding oral soy isoflavone to concurrent chemotherapy and&#xD;
      radiotherapy for the treatment of patients with unresectable stage III non-small cell lung&#xD;
      cancer (NSCLC).&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 of 2 treatment groups.&#xD;
&#xD;
      GROUP I (SQUAMOUS CELL HISTOLOGY): Patients receive etoposide intravenously (IV) over 1 hour&#xD;
      on days 1-5 and 29-33, cisplatin IV over 1 hour on days 1, 8, 29, and 36, and undergo&#xD;
      radiation therapy (RT) 5 days a week for 6.6 weeks. Within 48 hours of initiating treatment,&#xD;
      patients receive soy isoflavones orally (PO) daily on days 1-90.&#xD;
&#xD;
      GROUP II (NON-SQUAMOUS CELL HISTOLOGY): Patients receive pemetrexed disodium IV over 10&#xD;
      minutes on days 1, 22, and 43 and cisplatin IV over 1 hour on days 1, 22, and 43. Patients&#xD;
      also undergo RT and receive soy isoflavones as in Group I.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 4 weeks and then every 4&#xD;
      months for 1 year, every 6 months for 1 year, and then yearly thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">November 11, 2019</completion_date>
  <primary_completion_date type="Actual">October 9, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, in terms of dose-limiting toxicity of adding oral soy isoflavone supplementation to concurrent chemotherapy and radiotherapy, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4</measure>
    <time_frame>Up to 90 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival proportion</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade 3-4 toxicity rate graded according to NCI CTCAE version 4.0</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Point and exact confidence interval estimates of the grade 3-4 toxicity rate will be computed for each type of toxicity encountered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response (complete response [CR] and partial response [PR]) rate according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Point and exact confidence interval estimates of the (complete + partial) response rate will be computed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression (TTP)</measure>
    <time_frame>From the date of registration until the date that PD (progressive disease) or death is first reported, assessed up to 2 years</time_frame>
    <description>TTP will be estimated using standard Kaplan-Meier methods for censored data, from which the median and other statistics of interest will be calculated (e.g., rates at 3 months, 6 months, 12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From the date of registration to the date of death, assessed up to 2 years</time_frame>
    <description>OS will be estimated using standard Kaplan-Meier methods for censored data, from which the median and other statistics of interest will be calculated (e.g., rates at 3 months, 6 months, 12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>From the time that measurement criteria are first met for CR until the date that PD is objectively documented, assessed up to 2 years</time_frame>
    <description>Response duration will be estimated using standard Kaplan-Meier methods for censored data, from which the median and other statistics of interest will be calculated (e.g., rates at 3 months, 6 months, 12 months).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Adenocarcinoma of the Lung</condition>
  <condition>Adenosquamous Cell Lung Cancer</condition>
  <condition>Bronchoalveolar Cell Lung Cancer</condition>
  <condition>Large Cell Lung Cancer</condition>
  <condition>Recurrent Non-small Cell Lung Cancer</condition>
  <condition>Squamous Cell Lung Cancer</condition>
  <condition>Stage IIIA Non-small Cell Lung Cancer</condition>
  <condition>Stage IIIB Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Group I (squamous cell histology)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive etoposide IV over 1 hour on days 1-5 and 29-33, cisplatin IV over 1 hour on days 1, 8, 29, and 36, and undergo RT 5 days a week for 6.6 weeks. Within 48 hours of initiating treatment, patients receive soy isoflavones PO daily on days 1-90.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (non-squamous cell histology)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pemetrexed disodium IV over 10 minutes on days 1, 22, and 43 and cisplatin IV over 1 hour on days 1, 22, and 43. Patients also undergo RT and receive soy isoflavones as in Group I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>soy isoflavones</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group I (squamous cell histology)</arm_group_label>
    <arm_group_label>Group II (non-squamous cell histology)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (squamous cell histology)</arm_group_label>
    <arm_group_label>Group II (non-squamous cell histology)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (squamous cell histology)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed disodium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group II (non-squamous cell histology)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Undergo RT</description>
    <arm_group_label>Group I (squamous cell histology)</arm_group_label>
    <arm_group_label>Group II (non-squamous cell histology)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic or cytologic diagnosis of stage III non-small cell lung cancer; patients&#xD;
             will need to meet the following criteria for stage IIIA or IIIB diagnosis:&#xD;
&#xD;
               -  IIIA&#xD;
&#xD;
                    -  Histologic or cytologic diagnosis of ipsilateral mediastinal lymph node&#xD;
                       involvement, or&#xD;
&#xD;
                    -  Tumors greater than 7 cm or with chest wall invasion, or involvement of one&#xD;
                       of the following diaphragm, phrenic nerve, mediastinal pleura or parietal&#xD;
                       pericardium with hilar or mediastinal lymph node involvement&#xD;
&#xD;
                    -  More than one mediastinal lymph node enlarged on computed tomography (CT)&#xD;
                       scan and the same lymph nodes positive on positron emission tomography (PET)&#xD;
                       scans or&#xD;
&#xD;
                    -  Paralyzed left vocal cord with separate lung primary distinct from the&#xD;
                       aorto-pulmonary lymph nodes on the CT scan&#xD;
&#xD;
               -  IIIB&#xD;
&#xD;
                    -  Histologic or cytologic diagnosis of N3 lymph node involvement; or&#xD;
&#xD;
                    -  Enlarged N3 lymph nodes on CT scan that are positive on PET scan as well;&#xD;
                       patient must not have extension of lymph node involvement to cervical lymph&#xD;
                       nodes other than supraclavicular lymph nodes; or&#xD;
&#xD;
                    -  Right sided primary with left vocal cord paralysis; or&#xD;
&#xD;
                    -  Evidence of tumor extension into the mediastinum and/or mediastinal&#xD;
                       structures either at the time of mediastinoscopy, bronchoscopy or on CT&#xD;
                       scans&#xD;
&#xD;
                    -  Patients with a nodules in the same lung but no other areas of involvement&#xD;
&#xD;
                    -  Patients with prior surgically resected stage I NSCLC who did not receive&#xD;
                       any adjuvant therapy, who now have stage IIIA or B NSCLC will be eligible&#xD;
&#xD;
          -  Southwestern Oncology Group (SWOG) performance status 0 or 1&#xD;
&#xD;
          -  Absolute neutrophil count of &gt; 1.5 x 10^9/L&#xD;
&#xD;
          -  Platelet count &gt; 100,000 x 10^9/L&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 times the institutional upper limit of normal (ULN)&#xD;
&#xD;
          -  Calculated creatinine clearance (Cockcroft-Gault formula) of &gt;= 45mL/min&#xD;
&#xD;
          -  Serum bilirubin &gt; ULN&#xD;
&#xD;
          -  Transaminases (serum glutamic oxaloacetic transaminase [SGOT] and/or serum glutamate&#xD;
             pyruvate transaminase [SGPT]) &gt; 1.5 times institutional ULN&#xD;
&#xD;
          -  Alkaline phosphatase &gt;= 2.5 times ULN&#xD;
&#xD;
          -  Forced expiratory volume in one second (FEV1) of &gt;= 1 liter and diffusion capacity of&#xD;
             carbon monoxide (DLCO) &gt;= 40% of predicted&#xD;
&#xD;
          -  Patient should undergo brain imaging (CT scan or magnetic resonance imaging [MRI ]) to&#xD;
             rule out brain metastases&#xD;
&#xD;
          -  Signed informed consent that details the investigational nature of the study according&#xD;
             to institutional and federal guidelines&#xD;
&#xD;
          -  Registered with Clinical Trials Office at Karmanos Cancer Institute/Wayne State&#xD;
             University&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior chemotherapy, radiation for any malignancy in which they received any thoracic&#xD;
             radiotherapy&#xD;
&#xD;
          -  Patients with concurrent malignancy; patients with prior or concurrent malignancy will&#xD;
             be allowed as long as the treating physician considers it unlikely to impact the&#xD;
             clinical outcome of the patient&#xD;
&#xD;
          -  Patients with peripheral neuropathy &gt; 2&#xD;
&#xD;
          -  Serious medical illness including but not limited to uncontrolled congestive heart&#xD;
             failure, uncontrolled angina, myocardial infarction or cerebrovascular event with 6&#xD;
             months of registration, history of chronic active hepatitis or history of human&#xD;
             immunodeficiency virus (HIV) or an active bacterial infection will not be eligible&#xD;
&#xD;
          -  Inability or unwillingness to take folic acid or vitamin B12 or dexamethasone&#xD;
&#xD;
          -  Pregnant or lactating women; all pre-menopausal and peri-menopausal women should have&#xD;
             a urine test for pregnancy within a week of starting therapy; all patients of child&#xD;
             bearing potential should agree to use an effective contraceptive method&#xD;
&#xD;
          -  Patients should not participate in any other therapeutic investigational study while&#xD;
             taking part in this study&#xD;
&#xD;
          -  Patients on warfarin will not be allowed on the study; patient on low molecular&#xD;
             heparin or anti direct factor Xa inhibitor (Xa) drugs will be allowed&#xD;
&#xD;
          -  Patients with a soy allergy will be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shirish Gadgeel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karmanos Cancer Institute at McLaren Bay Region</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute at McLaren Lapeer Region</name>
      <address>
        <city>Lapeer</city>
        <state>Michigan</state>
        <zip>48446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute at McLaren Central Michigan</name>
      <address>
        <city>Mount Pleasant</city>
        <state>Michigan</state>
        <zip>48858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute at McLaren Northern</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 7, 2013</study_first_submitted>
  <study_first_submitted_qc>October 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2013</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Gerold Bepler</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
    <mesh_term>Adenocarcinoma, Bronchiolo-Alveolar</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

